You are using an older browser version. Please use a supported version for the best MSN experience.

Three doses of Pfizer vaccine provides ‘strong’ immunity for children 6 months to 5 years old, says pharmaceutical company

New York Daily News 5/23/2022 KATE FELDMAN

Three doses of a child-size Pfizer vaccine is not just safe but effective for children between the ages of 6 months and 5 years old, the company said Monday.

Pfizer plans to submit its trial data to the Food and Drug Administration this week as parents of young children push frantically for protection for their tots.

The trial, which used 1,678 children, injected a third dose of a 1/10th strength jab while Omicron was at its peak. A month later, antibody levels showed a similar immune response as 16-to-25-year-olds with two doses, Pfizer said.

The shot was “well tolerated” and most side effects were “mild or moderate.”

Video: Pfizer to submit Covid vaccine data for kids under age 5 this week (CNBC)


The first two doses in the trial were given three weeks apart and the final shot came at least two months later.

Children under 5 are still not eligible for a COVID-19 vaccine. © Rogelio V. Solis Children under 5 are still not eligible for a COVID-19 vaccine.

Children under 5 are still not eligible for a COVID-19 vaccine. (Rogelio V. Solis/)

“Our COVID-19 vaccine has been studied in thousands of children and adolescents, and we are pleased that our formulation for the youngest children, which we carefully selected to be one-tenth of the dose strength for adults, was well tolerated and produced a strong immune response,” Albert Bourla, the chairman and CEO at Pfizer, said in a statement.

“These topline safety, immunogenicity and efficacy data are encouraging, and we look forward to soon completing our submissions to regulators globally with the hope of making this vaccine available to younger children as quickly as possible, subject to regulatory authorization.”

Children under the age of 5 are the only group of the population not yet eligible for a COVID-19 vaccine. Moderna submitted its own data to the FDA in late April.

image beaconimage beaconimage beacon